Invitae, San Francisco, California, USA.
Geisinger, Genomic Medicine Institute, Danville, Pennsylvania, USA.
J Genet Couns. 2022 Oct;31(5):1219-1230. doi: 10.1002/jgc4.1592. Epub 2022 May 26.
Successful proband-mediated family communication and subsequent cascade genetic testing uptake requires interventions that present information clearly, in sufficient detail, and with medical authority. To facilitate family communication for patients receiving clinically actionable results via the MyCode® Community Health Initiative, a Family Sharing Tool (FST) and a cascade chatbot were developed. FST is an electronic mechanism allowing patients to share genetic test results with relatives via chatbot. The cascade chatbot describes the proband's result, associated disease risks, and recommended management and captures whether the user is a blood relative or caregiver, sex, and relationship to the proband. FST and cascade chatbot uptake among MyCode® probands and relatives was tracked from August 2018 through February 2020. Cascade genetic testing uptake was collected from testing laboratories as number of cascades per proband. Fifty-eight percent (316/543) of probands consented to FST; 42% (227/543) declined. Receipt preferences were patient electronic health record (EHR) portal (52%), email (29%), and text (19%). Patient EHR portal users (p < 0.001) and younger patients were more likely to consent (p < 0.001). FST was deployed to 308 probands. Fifty-nine percent (183/308) opened; of those, 56% (102/183) used FST to send a cascade chatbot to relatives. These 102 probands shared a cascade chatbot with 377 relatives. Sixty-two percent (235/377) of relatives opened; of these, 69% (161/235) started, and of these, 57% (92/161) completed the cascade chatbot. Cascade genetic testing uptake was significantly greater among relatives of probands who consented to the FST (M = 2.34 cascades, SD = 2.10) than relatives of probands who declined (M = 1.40 cascades, SD = 0.82, p < 0.001). Proband age was not a significant predictor of cascade genetic testing uptake. Further work is needed to better understand factors impacting proband use of FST and relative use of cascade chatbots.
成功的先证者介导的家庭沟通以及随后的级联遗传检测采用需要干预措施,这些措施需要清晰、充分地呈现信息,并具有医学权威性。为了促进通过 MyCode®社区健康倡议接受临床可操作结果的患者的家庭沟通,开发了一种家庭共享工具(FST)和级联聊天机器人。FST 是一种允许患者通过聊天机器人与亲属共享遗传测试结果的电子机制。级联聊天机器人描述了先证者的结果、相关疾病风险以及建议的管理措施,并捕获用户是否是血缘亲属或护理人员、性别以及与先证者的关系。从 2018 年 8 月到 2020 年 2 月,对 MyCode®先证者及其亲属的 FST 和级联聊天机器人采用情况进行了跟踪。级联遗传检测采用情况从检测实验室收集,每个先证者的级联数。58%(316/543)的先证者同意 FST;42%(227/543)拒绝。收件人偏好为患者电子健康记录(EHR)门户(52%)、电子邮件(29%)和短信(19%)。患者 EHR 门户用户(p<0.001)和年轻患者更有可能同意(p<0.001)。FST 已部署到 308 名先证者。59%(183/308)打开;其中,56%(102/183)使用 FST 将级联聊天机器人发送给亲属。这 102 名先证者与 377 名亲属共享了级联聊天机器人。62%(235/377)的亲属打开了聊天机器人;其中,69%(161/235)开始,其中,57%(92/161)完成了级联聊天机器人。与同意 FST 的先证者的亲属相比,不同意 FST 的先证者的亲属的级联遗传检测采用率显著更高(M=2.34 级联,SD=2.10)(p<0.001)。先证者年龄不是级联遗传检测采用的显著预测因素。需要进一步研究以更好地了解影响先证者使用 FST 和亲属使用级联聊天机器人的因素。